Interaction between bone morphogenetic protein receptor type 2 and estrogenic compounds in pulmonary arterial hypertension

Pulmonary Circulation

Volumn 3, Issue 3, 2013, Pages 564-577

  Fessel, Joshua P ^a   Chen, Xinping ^a   Frump, Andrea ^a   Gladson, Santhi ^a   Blackwell, Tom ^a   Kang, Christie ^a   Johnson, Jennifer ^a   Loyd, James E ^a   Hemnes, Anna ^a   Austin, Eric ^a   West, James ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bmp; Estrogen; Insulin; Metabolism; Pulmonary hypertension; Wnt

Indexed keywords

EID: 84903641935     PISSN: 20458932     EISSN: 20458940     Source Type: Journal    
DOI: 10.1086/674312     Document Type: Article

References (45)

1. Lane KB, Machado RD, Pauciulo MW, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet 2000;26:81-84.
2. Machado RD, Pauciulo MW, Thomson JR, et al. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet 2001;68:92-102.
3. Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL registry. Chest 2010;137:376-387.
4. Chin KM, Rubin LJ. Pulmonary arterial hypertension. J Am Coll Cardiol 2008;51:1527-1538.
5. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006;173:1023-1030.
6. Napoli N, Thompson J, Civitelli R, Armamento-Villareal RC. Effects of dietary calcium compared with calcium supplements on estrogen metabolism and bone mineral density. Am J Clin Nutr 2007;85:1428-1433.
7. Mueck AO, Seeger H. 2-Methoxyestradiol—biology and mechanism of action. Steroids 2010;75:625-631.
8. Austin ED, Cogan JD, West JD, et al. Alterations in oestrogen metabolism: implications for higher penetrance of familial pulmonary arterial hypertension in females. Eur Respir J 2009;34:1093-1099.
9. West J, Cogan J, Geraci M, et al. Gene expression in BMPR2 mutation carriers with and without evidence of pulmonary arterial hypertension suggests pathways relevant to disease penetrance. BMC Med Genomics 2008;1:45.
10. Lahm T, Albrecht M, Fisher AJ, et al. 17β-Estradiol attenuates hypoxic pulmonary hypertension via estrogen receptor-mediated effects. Am J Respir Crit Care Med 2012;185:965-980.
11. Tofovic SP. Estrogens and development of pulmonary hypertension: interaction of estradiol metabolism and pulmonary vascular disease. J Cardiovasc Pharmacol 2010;56:696-708.
12. Lahm T, Crisostomo PR, Markel TA, et al. The effects of estrogen on pulmonary artery vasoreactivity and hypoxic pulmonary vasoconstriction: potential new clinical implications for an old hormone. Crit Care Med 2008;36:2174-2183.
13. Yasuda T, Tada Y, Tanabe N, Tatsumi K, West J. Rho-kinase inhibition alleviates pulmonary hypertension in transgenic mice expressing a dominant-negative type II bone morphogenetic protein receptor gene. Am J Physiol Lung Cell Mol Physiol 2011;301:L667-L674.
14. Johnson JA, Hemnes AR, Perrien DS, et al. Cytoskeletal defects in Bmpr2-associated pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2012;302:L474-L484.
15. West J, Harral J, Lane K, et al. Mice expressing BMPR2R899X transgene in smooth muscle develop pulmonary vascular lesions. AmJ Physiol Lung Cell Mol Physiol 2008;295:L744-L755.
16. West J, Niswender KD, Johnson JA, et al. A potential role for insulin resistance in experimental pulmonary hypertension. Eur Respir J 2013;41:861-871.
17. Pozzi A, Moberg PE, Miles LA, Wagner S, Soloway P, Gardner HA. Elevated matrix metalloprotease and angiostatin levels in integrin α1 knockout mice cause reduced tumor vascularization. Proc Natl Acad Sci USA 2000;97:2202-2207.
18. Lane KB, Talati M, Austin E, et al. Oxidative injury is a common consequence of BMPR2 mutations. Pulm Circ 2011;1:72-83.
19. Zhang B, Kirov S, Snoddy J. WebGestalt: an integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res 2005;33:W741-W748.
20. Austin ED, Menon S, Hemnes AR, et al. Idiopathic and heritable PAH perturb common molecular pathways, correlated with increased MSX1 expression. Pulm Circ 2011;1: 389-398.
21. Hao L, Klein J, Nei M. Heterogeneous but conserved natural killer receptor gene complexes in four major orders of mammals. Proc Natl Acad Sci USA 2006;103:3192-3197.
22. Mommsen P, Barkhausen T, Hildebrand F, Zeckey C, Krettek C, van Griensven M. Regulation of L-selectin expression by trauma-relevant cytokines. Pathol Res Pract 2011; 207:142-147.
23. Menzies FM, Henriquez FL, Alexander J, Roberts CW. Selective inhibition and augmentation of alternative macrophage activation by progesterone. Immunology 2011;134:281-291.
24. Lustig RH, Mobbs CV, Pfaff DW, Fishman J. Temporal actions of 16 alpha-hydroxyestrone in the rat: comparisons of lordosis dynamics with other estrogen metabolites and between sexes. J Steroid Biochem 1989;33:417-421.
25. White K, Johansen AK, Nilsen M, et al. Activity of the estrogen-metabolizing enzyme cytochrome P450 1B1 influences the development of pulmonary arterial hypertension. Circulation 2012;126:1087-1098.
26. Johnson JA, Hemnes AR, Perrien DS, et al. Cytoskeletal defects in Bmpr2-associated pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2012;302:L474-L484.
27. Majka S, Hagen M, Blackwell T, et al. Physiologic and molecular consequences of endothelial Bmpr2 mutation. Respir Res 2011;12:84.
28. Hong KH, Lee YJ, Lee E, et al. Genetic ablation of the Bmpr2 gene in pulmonary endothelium is sufficient to predispose to pulmonary arterial hypertension. Circulation 2008;118: 722-730.
29. Yasuda T, Tada Y, Tanabe N, Tatsumi K, West J. Rho-kinase inhibition alleviates pulmonary hypertension in transgenic mice expressing a dominant-negative type II bone morphogenetic protein receptor gene. Am J Physiol Lung Cell Mol Physiol 2011;301:L667-L674.
30. Tada Y, Laudi S, Harral J, et al. Murine pulmonary response to chronic hypoxia is strain specific. Exp Lung Res 2008;34: 313-323.
31. Austin ED, Hamid R, Hemnes AR, et al. BMPR2 expression is suppressed by signaling through the estrogen receptor. Biol Sex Differ 2012;3:6.
32. Durrington HJ, Upton PD, Hoer S, et al. Identification of a lysosomal pathway regulating degradation of the bone morphogenetic protein receptor type II. J Biol Chem 2010;285: 37641-37649.
33. Burlando B, Marchi B, Panfoli I, Viarengo A. Essential role of Ca2+-dependent phospholipase A2 in estradiol-induced lysosome activation. Am J Physiol Cell Physiol 2002;283:C1461-C1468.
34. Hou X, Tan Y, Li M, Dey SK, Das SK. Canonical Wnt signaling is critical to estrogen-mediated uterine growth. Mol Endocrinol 2004;18:3035-3049.
35. de Jesus Perez VA, Alastalo TP, Wu JC, et al. Bone morphogenetic protein 2 induces pulmonary angiogenesis via Wnt-β-catenin and Wnt-RhoA-Rac1 pathways. J Cell Biol 2009;184:83-99.
36. Powazniak Y, Kempfer AC, Pereyra JC, Palomino JP, Lazzari MA. VWF and ADAMTS13 behavior in estradiol-treated HUVEC. Eur J Haematol 2011;86:140-147.
37. Helmestam M, Andersson H, Stavreus-Evers A, Brittebo E, Olovsson M. Tamoxifen modulates cell migration and expression of angiogenesis-related genes in human endometrial endothelial cells. Am J Pathol 2012;180:2527-2535.
38. Tchaikovski SN, Rosing J. Mechanisms of estrogen-induced venous thromboembolism. Thromb Res 2010;126:5-11.
39. Anderson JA, Weitz JI. Hypercoagulable states. Clin Chest Med 2010;31:659-673.
40. Caja S, Puerta M. Control by reproduction-related hormones of resistin expression and plasma concentration. Horm Metab Res 2007;39:501-506.
41. Lee MJ, Lin H, Liu CW, et al. Octylphenol stimulates resistin gene expression in 3T3-L1 adipocytes via the estrogen receptor and extracellular signal-regulated kinase pathways. Am J Physiol Cell Physiol 2008;294:C1542-C1551.
42. Donn R, Berry A, Stevens A, et al. Use of gene expression profiling to identify a novel glucocorticoid sensitivity determining gene, BMPRII. FASEB J 2007;21:402-414.
43. Zhu BT, Han GZ, Shim JY, Wen Y, Jiang XR. Quantitative structure-activity relationship of various endogenous estrogen metabolites for human estrogen receptor α and β subtypes: insights into the structural determinants favoring a differential subtype binding. Endocrinology 2006;147:4132-4150.
44. Swaneck GE, Fishman J. Covalent binding of the endogenous estrogen 16α-hydroxyestrone to estradiol receptor in human breast cancer cells: characterization and intranuclear localization. Proc Natl Acad Sci USA 1988;85:7831-7835.
45. Miyairi S, Maeda K, Oe T, Kato T, Naganuma A. Effect of metal ions on the stable adduct formation of 16α-hydroxyestrone with a primary amine via the Heyns rearrangement. Steroids 1999;64:252-258.